Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Nabil Adra, Costantine Albany, Mary J Brames, Somer Case-Eads, Cynthia S Johnson, Ziyue Liu, Christopher A Fausel, Timothy Breen, Nasser H Hanna, Ralph J Hauke, Joel Picus, Lawrence H Einhorn, Nabil Adra, Costantine Albany, Mary J Brames, Somer Case-Eads, Cynthia S Johnson, Ziyue Liu, Christopher A Fausel, Timothy Breen, Nasser H Hanna, Ralph J Hauke, Joel Picus, Lawrence H Einhorn

Abstract

Purpose: A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (CR) (J Clin Onc 30:3998-4003, 2012). Fosaprepitant has demonstrated non-inferiority compared to aprepitant in single-day cisplatin chemotherapy and is approved as a single-dose alternative. This single-arm phase II study is the first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin regimen.

Methods: GCT patients receiving a 5-day cisplatin combination chemotherapy were enrolled. Fosaprepitant 150 mg was given IV on days 3 and 5. A 5HT3-RA days 1-5 (days 1, 3, and 5, if palonosetron) plus dexamethasone 20 mg days 1 and 2 and 4 mg po bid days 6, 7, and 8 was administered. Rescue antiemetics were allowed. The primary objective was to determine the CR rate-no emetic episodes or use of rescue medications. Accrual of 64 patients was planned with expected CR > 27 %.

Results: Sixty-five patients were enrolled of whom 54 were eligible for analysis. Median age was 33. Fifty-one patients received bleomycin, etoposide, and cisplatin (BEP) chemotherapy. CR was observed in 13 (24.1 %) patients (95 % Agresti-Coull binomial C.I. 14.5 %, 37.1 %).

Conclusion: The data in this phase II study, in contrast to our prior phase III study, appears to indicate a lower CR rate with the substitution of fosaprepitant for aprepitant. It is unknown whether the substitution of fosaprepitant for aprepitant provides the same benefit in multi-day cisplatin that was achieved with single-day cisplatin. Trial registration Clinical trial information NCT01736917.

Keywords: Chemotherapy-induced nausea and vomiting; Fosaprepitant; Germ cell tumor; Testicular cancer.

References

    1. J Clin Pharmacol. 2007 Jul;47(7):834-40
    1. J Clin Oncol. 1994 Mar;12(3):596-600
    1. J Clin Oncol. 2001 Mar 15;19(6):1759-67
    1. J Clin Oncol. 2003 Nov 15;21(22):4112-9
    1. Ann Oncol. 2013 Apr;24(4):1067-73
    1. N Engl J Med. 1990 Mar 22;322(12):810-6
    1. J Clin Oncol. 2006 Sep 20;24(27):4472-8
    1. Cancer. 2004 May 15;100(10):2261-8
    1. Br J Cancer. 2006 Apr 10;94(7):1011-5
    1. Support Care Cancer. 2002 Mar;10(2):85-7
    1. J Clin Oncol. 2011 Apr 10;29(11):1495-501
    1. J Med Chem. 2000 Mar 23;43(6):1234-41
    1. J Clin Oncol. 1990 Apr;8(4):731-5
    1. Cancer. 2005 Aug 15;104(4):864-8
    1. J Clin Oncol. 2012 Nov 10;30(32):3998-4003
    1. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4592-5
    1. J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12
    1. Cancer. 2003 May 1;97(9):2290-300
    1. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
    1. Br J Cancer. 2001 Nov 30;85(11):1624-6
    1. Clin Exp Optom. 2002 Mar;85(2):61-75
    1. Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4
    1. N Engl J Med. 1979 Jun 7;300(23):1295-7

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner